Mapping of brain tau deposition in tauopathy by PET with [11C]PBB3

Not Applicable

• Conditions: Healthy volunteers 20 years of age or older at the time of obtaining consent Patients with mild cognitive impairment (MCI) 20 years of age or older at the time of obtaining consent Patients with Alzheimer' s disease (AD) 20 years of age or older at the time of obtaining consent Patients with corticobasal degeneration (CBD) 20 years of age or older at the time of obtaining consent Patients with progressive supranuclear palsy (PSP) 20 years of age or older at the time of obtaining consent Patients with frontotemporal dementia (FTD) 20 years of age or older at the time of obtaining consent Patients with familial Parkinson' s disease with the LRRK2 genetic mutation (PARK8)

• Registration Number: JPRN-UMIN000009863
• Lead Sponsor: ational Institute of Radiological Sciences

Brief Summary

The distribution of tau PET ([11C]PBB3-PET) were consistent with pathological findings. The increased accumulation was associated with the severity of dementia and brain atrophy.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-02-14
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

Not provided

Exclusion Criteria

healthy volunteer 1. Subjects with organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2. Patients with substance-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3. Subjects with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by the aforementioned doctors with responsibilities in this study. 4. Subjects with a pacemaker or other metallic medical device in the body (brain clip, bolts, etc.). 5. Subjects with tattoos. Subjects with claustrophobia. 6. Pregnant, possibly pregnant or lactating women. 7. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study. 8. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study. Patients with MCI, AD, CBD, PSP, FTD and PARK8 1. Patients with other organic brain complications/disorders (including a history of symptomatic cerebral infarction, Parkinson's disease and similar conditions). 2. Patients with substance-related disorders (including drug abuse). For the acceptable range of allowable drugs. 3. Patients with severe physical complications/disorders or a history of such conditions and who are considered to be inappropriate for participation by doctors with responsibilities in this study. 4. Patients with claustrophobia. 5. Pregnant, possibly pregnant or lactating women. 6. Patients who are considered to be inappropriate for participation by doctors with responsibilities in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Distribution volume and binding potential measured by positron emission tomography with [11C]PBB3 - Comparison between patients and age- and gender-matched healthy controls